World Journal of
Pharmaceutical and Life Sciences

LC–MS–ASSISTED CHARACTERIZATION AND THERAPEUTIC ASSESSMENT OF VINDESINE IN EYE CANCER CELL LINE MODELS

Dr. Syed Ahmed Hussain*, Somabatthini Shruthi, Ghousia Begum, Nada Ahmed Al Amoodi, Fariya Sultana, Bilquis Begum, Ayesha Ayub Khan, Muskan Khatoon

ABSTRACT

This study evaluates the comparative in vitro pharmacological profiles of Vindesine and Vinblastine in eye cancer cell line models, including retinoblastoma (Y79, WERI-Rb1) and uveal melanoma (OCM-1, 92.1). A five-assay panel was employed to assess both cell viability and cytotoxicity. In viability assays (Resazurin/Alamar Blue and ATP Luminescence), Vindesine maintained 88–90% cell survival, indicating mild cytostatic activity, while Vinblastine showed complete viability (100%). Cytotoxicity evaluation through Annexin V/PI staining, Caspase-3/7 activation, and LDH release revealed that Vindesine induced moderate apoptosis (20%), mild caspase activation (1.5-fold), and limited membrane damage (16%), whereas Vinblastine remained largely non-toxic (7% apoptosis, 1.0-fold, 8% LDH). Collectively, Vindesine exhibited controlled apoptotic potential without extensive necrosis, suggesting a balanced cytostatic-cytotoxic profile advantageous for long-term ocular chemotherapy. These results propose Vindesine as a viable alternative vinca alkaloid with slightly enhanced pro-apoptotic efficiency and a favorable safety margin in eye cancer therapeutic modeling.

[Full Text Article]   [Download Certificate]